JP2024506145A5 - - Google Patents
Info
- Publication number
- JP2024506145A5 JP2024506145A5 JP2023546450A JP2023546450A JP2024506145A5 JP 2024506145 A5 JP2024506145 A5 JP 2024506145A5 JP 2023546450 A JP2023546450 A JP 2023546450A JP 2023546450 A JP2023546450 A JP 2023546450A JP 2024506145 A5 JP2024506145 A5 JP 2024506145A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutical composition
- compound
- compound according
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163144696P | 2021-02-02 | 2021-02-02 | |
| US63/144,696 | 2021-02-02 | ||
| PCT/US2022/014728 WO2022169757A1 (en) | 2021-02-02 | 2022-02-01 | Half-life extending moieties and methods of using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024506145A JP2024506145A (ja) | 2024-02-09 |
| JP2024506145A5 true JP2024506145A5 (cg-RX-API-DMAC10.html) | 2025-02-10 |
Family
ID=80735776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023546450A Pending JP2024506145A (ja) | 2021-02-02 | 2022-02-01 | 半減期延長部分及びその使用方法 |
Country Status (18)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20260109751A1 (en) * | 2022-12-30 | 2026-04-23 | Eli Lilly And Company | Methods of dulaglutide purification using hydrophobic interaction chromatography |
| EP4731669A2 (en) * | 2023-06-21 | 2026-04-29 | Eli Lilly and Company | Compounds for the delivery of granulin across the blood brain barrier |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2259802A1 (en) * | 2008-03-31 | 2010-12-15 | Glaxo Group Limited | Drug fusions and conjugates |
| AU2012280474A1 (en) * | 2011-07-01 | 2014-01-16 | Bayer Intellectual Property Gmbh | Relaxin fusion polypeptides and uses thereof |
| AU2015231170B2 (en) * | 2014-03-20 | 2019-10-03 | Bristol-Myers Squibb Company | Serum albumin-binding fibronectin type III domains |
| WO2018104444A1 (en) * | 2016-12-07 | 2018-06-14 | Ablynx Nv | Improved serum albumin binding immunoglobulin single variable domains |
| EP3807311A4 (en) * | 2018-04-24 | 2022-01-26 | National Research Council of Canada | SERUM ALBUM BINDING ANTIBODIES FOR TUNABLE HALF-LIFE OF BIOLOGICALS |
| TWI844709B (zh) * | 2019-07-31 | 2024-06-11 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
-
2022
- 2022-02-01 JP JP2023546450A patent/JP2024506145A/ja active Pending
- 2022-02-01 CA CA3204225A patent/CA3204225A1/en active Pending
- 2022-02-01 KR KR1020237025927A patent/KR20230137342A/ko active Pending
- 2022-02-01 EP EP22709849.8A patent/EP4288452A1/en active Pending
- 2022-02-01 US US18/259,500 patent/US20240316154A1/en active Pending
- 2022-02-01 MX MX2023009006A patent/MX2023009006A/es unknown
- 2022-02-01 WO PCT/US2022/014728 patent/WO2022169757A1/en not_active Ceased
- 2022-02-01 AU AU2022217754A patent/AU2022217754A1/en active Pending
- 2022-02-01 CN CN202280012629.0A patent/CN116802209A/zh active Pending
- 2022-02-01 CR CR20230366A patent/CR20230366A/es unknown
- 2022-02-01 PE PE2023002220A patent/PE20240233A1/es unknown
-
2023
- 2023-06-30 ZA ZA2023/06754A patent/ZA202306754B/en unknown
- 2023-07-03 IL IL304219A patent/IL304219A/en unknown
- 2023-07-27 DO DO2023000149A patent/DOP2023000149A/es unknown
- 2023-07-27 CO CONC2023/0010002A patent/CO2023010002A2/es unknown
- 2023-07-30 JO JOJO/P/2023/0173A patent/JOP20230173A1/ar unknown
- 2023-08-01 EC ECSENADI202358246A patent/ECSP23058246A/es unknown
- 2023-08-02 CL CL2023002285A patent/CL2023002285A1/es unknown
-
2025
- 2025-10-02 CL CL2025003008A patent/CL2025003008A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0346429B1 (en) | Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2) | |
| US6509154B1 (en) | Product comprising at least a double stranded RNA combined with at least an antiviral agent | |
| KR20110049797A (ko) | 장기 작용성 인터페론 및 그의 유도체 및 그 방법 | |
| CN116531368A (zh) | 一种glp-1r激动剂 | |
| JPS63501567A (ja) | 生長因子 | |
| RU2001136014A (ru) | Агонисты рецептора-3 (r3) пептида-активатора гипофизарной аденилатциклазы(расар) и способы их фармакологического применения | |
| JP2005527547A (ja) | トレフォイル・ペプチドを使用した組み合わせ療法 | |
| KR970705405A (ko) | 사람 케모킨 폴리펩타이드(Human Chemokine Polypeptides) | |
| JP2024541120A (ja) | 治療薬の経口送達 | |
| JP2021514354A5 (cg-RX-API-DMAC10.html) | ||
| WO2024193606A1 (zh) | 肠促胰岛素类似物及其应用 | |
| JP2025114869A5 (cg-RX-API-DMAC10.html) | ||
| JP2005515214A5 (cg-RX-API-DMAC10.html) | ||
| JP2001501177A (ja) | Ｏｂタンパク質受容体をアップレギュレートすることによりｏｂタンパク質に対する個体の感受性を増加させる方法 | |
| JP2025500874A5 (cg-RX-API-DMAC10.html) | ||
| CN1334742A (zh) | 促生长素抑制素类似物兰瑞肽的应用方法 | |
| CN105884901B (zh) | 具持续控制血糖含量功能的重组人血清白蛋白/胰高糖素类肽融合蛋白 | |
| WO2025098335A1 (zh) | 一类多肽在制备治疗肥胖及其合并症的药物、食品或保健品中的用途 | |
| EP4419130B1 (en) | Il-4 derived peptides for use in the treatment of obesity | |
| US20220143150A1 (en) | Glucagon-like peptide-1 (glp-1) agonist analog, process of preparation and uses thereof | |
| JPWO2002030464A1 (ja) | 新規肝疾患用薬 | |
| JP2022508619A5 (cg-RX-API-DMAC10.html) | ||
| CN115947821B (zh) | 一种glp-1类似物 | |
| US20080045609A1 (en) | Methods and therapeutics to facilitate liver repair | |
| EP3426678B1 (en) | Conjugates of islet neogenesis peptides and analogs, and methods thereof |